Ilika raises £0.9m in upsized retail offer

Ilika plc

Further to the announcement by the Company in respect of the Retail Offer dated 22 May 2025, Ilika plc (LON:IKA), has announced that, following the closing of the Retail Offer on the BookBuild platform on 28 May 2025, the Retail Offer was significantly oversubscribed. Accordingly, the Company has elected to increase scale of the Retail Offer to raise total gross proceeds of £0.9 million through the issue of 2,727,273 Retail Offer Shares at the Issue Price of 33 pence per share.

Consequently, it is anticipated that 9,884,017 Placing Shares, 81,819 Director Subscription Shares and 2,727,273 Retail Offer Shares resulting in a total of 12,693,109 New Ordinary Shares being issued in relation to the Fundraising. The total gross monies raised (before expenses) is approximately £4.2 million. The proceeds will be used as outlined in the retail offer announcement dated 22 May 2025 with the excess being proportionately assigned to further advance the commercial status of both of the Company’s product lines.

Allocations were made to existing Shareholders, applying the principles of soft pre-emption.  Given the significant demand, existing Shareholders received 100 per cent. of their soft pre-emptive allowance, when their order matched or exceeded their soft pre-emptive allowance. Where the order was greater than the soft pre-emptive allowance shareholders received c. 89.97 per cent of their additional demand1.

Other than where defined, capitalised terms used in this announcement have the meanings given to them in the Retail Offer Announcement.

Total Voting Rights

Following Admission of the New Ordinary Shares, the Company will have 180,802,175 Ordinary Shares in issue with the Company holding no Ordinary Shares in treasury. Therefore, the total number of voting rights will also be 180,802,175. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of Ilika Plc under the FCA’s Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika’s Stereax batteries set for Medical Technology Ireland showcase

Ilika’s Stereax batteries will be showcased by Cirtec Medical at Medical Technology Ireland, giving the company targeted exposure in the medical device market.

Ilika CEO Graeme Purdy discusses Stereax revenues and Goliath opportunities

Ilika CEO Graeme Purdy discusses first Stereax revenues, grant support for Goliath, EV market trends, and opportunities in defence and e-bikes.

Ilika positions solid state batteries for the future of implantable neurostimulation

Ilika’s Stereax solid state battery technology supports the development of smaller, safer and more practical implantable neurostimulation devices for emerging medical applications.

Ilika advances manufacturing readiness for solid-state batteries

Ilika’s collaboration with UKBIC shows how manufacturing validation is helping move its Goliath pouch cell technology closer to commercial readiness.

Ilika reports first Stereax revenues and Goliath progress

Ilika expects FY26 revenue of approximately £1.1m, including first commercial Stereax electrode sales, with Goliath evaluation activity expanding across automotive, defence and e-bike applications.

Search